The battle of drug-resistant bacteria, Shandong New Line Biotechnology and Ningbo Research Institute of National Science and Technology join hands to break the game!
山东新航线生物科技有限公司 Shandong New Line Biotechnology Co., Ltd.
国科宁波生命与健康产业研究院 Guoke Ningbo Life and Health Industry Research Institute
举行战略合作签约仪式 held a strategic cooperation signing ceremony
2024年3月13日，山东新航线生物科技有限公司与国科宁波生命与健康产业研究院就“临床耐药菌噬菌体制剂开发”项目缔结战略合作关系，对“临床耐药菌噬菌体制剂开发并基于类器官探究其安全性有效性”进行市场推广应用，并结合市场需求，对系统进行创新新探索和升级改造，增强市场竞争力。
On March 13, 2024, Shandong New Line Biotechnology Co., Ltd. entered into a strategic cooperation relationship with Ningbo Institute of Life and Health Industry of Guoke on the project of “Development of Clinical Drug Resistant Bacteriophage Preparations”, promoted and applied the “Development of Clinical Drug Resistant Bacteriophage Preparations and Exploration of Their Safety and Effectiveness Based on Organoids”, and innovated and upgraded the system in combination with market demand to enhance market competitiveness.
){kind=small}
山东新航线生物科技有限公司董事长王国强、研发总监熊海涛博士，国科宁波生命与健康产业研究院院长蔡挺、研究组负责人孙越超博士等出席了签约仪式。
Wang Guoqiang, Chairman of Shandong New Line Biotechnology Co., Ltd., Dr. Xiong Haitao, Director of R & D, Cai Ting, President of Ningbo Institute of Life and Health Industry of National Science and Technology, Dr. Sun Yuechao, Head of Research Group, attended the signing ceremony.
)
国科宁波生命与健康产业研究院（以下简称“研究院”）是由宁波市政府牵头建设的高端、高质、高效的科学研究联合体。自2018年成立以来，研究院以“健康中国”国家战略为引领，以产学研合作为依托，不断加强与国内外著名科研机构的交流合作，积极参与医疗技术研发、生物医药发展、健康大数据产业等社会服务，深入开展重大疾病诊治和精准医学、智慧医疗的关键技术研究，并转化研究成果，致力于推动生命健康领域的重大科技创新，培养高水平的科研人才队伍。研究院目前已成功申报国家自然科学基金及省部级各类重大科研项目、浙江省自然科学基金、宁波市甬江引才工程、宁波市科技创新2025重大专项等项目。旨在促进宁波市生物医药、高端制造和生命健康产业升级。
Ningbo Institute of Life and Health Industry (hereinafter referred to as “Institute”) is a high-end, high-quality and efficient scientific research consortium led by Ningbo City Government. Since its establishment in 2018, the Institute has been guided by the national strategy of “Healthy China” and supported by industry-university-research cooperation. It has continuously strengthened exchanges and cooperation with famous scientific research institutions at home and abroad, actively participated in social services such as medical technology research and development, biomedical development, and health big data industry, carried out in-depth research on key technologies for diagnosis and treatment of major diseases, precision medicine, and intelligent medicine, and transformed research results. It is committed to promoting major scientific and technological innovations in the field of life and health. cultivate a contingent of high-level scientific research personnel. At present, the Institute has successfully applied for various major scientific research projects at the national natural science foundation and provincial and ministerial levels, natural science foundation of Zhejiang Province, Yongjiang talent introduction project of Ningbo City, and major special projects of science and technology innovation 2025 of Ningbo City. It aims to promote the upgrading of biological medicine, high-end manufacturing and life and health industries in Ningbo City.
)
此次战略合作的达成，标志着双方将在未来的生物医药领域展开更深入的合作，将为噬菌体制剂的开发和应用提供强大的技术支持和市场资源，还将对“临床耐药菌噬菌体制剂开发并基于类器官探究其安全性有效性”的市场推广应用进行创新探索和升级改造，这无疑将增强市场竞争力，为基础医学和临床医学研究提供生物样本，此平台也将为项目后期开展噬菌体临床转化研究提供必要支撑。
The conclusion of this strategic cooperation marks that both parties will carry out more in-depth cooperation in the future biomedical field, provide strong technical support and market resources for the development and application of phage preparations, and also carry out innovative exploration and upgrading of the market promotion and application of “clinical drug-resistant phage preparation development and organoid based exploration of its safety and effectiveness”, which will undoubtedly enhance market competitiveness and provide biological samples for basic medicine and clinical medical research. This platform will also provide necessary support for phage clinical transformation research in the later stage of the project.